Mark Talamonti
Concepts (682)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 84 | 2022 | 603 | 11.560 |
Why?
| Pancreatectomy | 35 | 2022 | 136 | 4.690 |
Why?
| Psoriasis | 14 | 2020 | 228 | 4.610 |
Why?
| Adenocarcinoma | 45 | 2019 | 1126 | 4.560 |
Why?
| Pancreaticoduodenectomy | 22 | 2020 | 73 | 3.610 |
Why?
| Carcinoma, Pancreatic Ductal | 21 | 2022 | 93 | 3.320 |
Why?
| Dermatologic Agents | 7 | 2019 | 70 | 2.710 |
Why?
| HLA-C Antigens | 3 | 2017 | 22 | 1.790 |
Why?
| Aged | 109 | 2021 | 17525 | 1.700 |
Why?
| Laparoscopy | 16 | 2019 | 675 | 1.630 |
Why?
| Middle Aged | 112 | 2021 | 24057 | 1.580 |
Why?
| Liver Neoplasms | 13 | 2021 | 636 | 1.540 |
Why?
| Neoplasm Staging | 33 | 2018 | 1882 | 1.460 |
Why?
| Neuroendocrine Tumors | 8 | 2014 | 86 | 1.430 |
Why?
| Bile Duct Neoplasms | 4 | 2021 | 60 | 1.380 |
Why?
| Antibodies, Monoclonal | 9 | 2018 | 1377 | 1.350 |
Why?
| Humans | 192 | 2022 | 80750 | 1.350 |
Why?
| Antibodies, Monoclonal, Humanized | 12 | 2021 | 900 | 1.270 |
Why?
| Pancreatic Fistula | 6 | 2020 | 13 | 1.250 |
Why?
| Male | 121 | 2021 | 39628 | 1.250 |
Why?
| Postoperative Complications | 18 | 2022 | 2094 | 1.250 |
Why?
| Carcinoma | 7 | 2012 | 426 | 1.230 |
Why?
| Female | 123 | 2021 | 42514 | 1.220 |
Why?
| Biliary Tract Neoplasms | 3 | 2012 | 29 | 1.160 |
Why?
| Retrospective Studies | 56 | 2022 | 7529 | 1.160 |
Why?
| Treatment Outcome | 48 | 2022 | 7550 | 1.100 |
Why?
| Colorectal Neoplasms | 12 | 2020 | 865 | 1.030 |
Why?
| Deoxycytidine | 10 | 2018 | 235 | 1.020 |
Why?
| Ampulla of Vater | 4 | 2014 | 22 | 0.990 |
Why?
| Aged, 80 and over | 37 | 2021 | 6231 | 0.950 |
Why?
| Adult | 62 | 2021 | 24668 | 0.900 |
Why?
| Portal Vein | 2 | 2021 | 115 | 0.880 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2017 | 2325 | 0.870 |
Why?
| Pancreatic Diseases | 4 | 2020 | 46 | 0.870 |
Why?
| Endosonography | 3 | 2015 | 92 | 0.860 |
Why?
| Neoadjuvant Therapy | 11 | 2016 | 274 | 0.850 |
Why?
| Venous Thromboembolism | 2 | 2022 | 121 | 0.850 |
Why?
| Rectal Neoplasms | 5 | 2007 | 113 | 0.830 |
Why?
| Pancreatic Cyst | 5 | 2009 | 27 | 0.830 |
Why?
| Survival Analysis | 25 | 2017 | 1521 | 0.830 |
Why?
| General Surgery | 2 | 2022 | 215 | 0.800 |
Why?
| Biological Therapy | 1 | 2020 | 45 | 0.790 |
Why?
| Organizational Innovation | 2 | 2020 | 35 | 0.790 |
Why?
| Stents | 4 | 2021 | 355 | 0.770 |
Why?
| Acrodermatitis | 1 | 2019 | 3 | 0.760 |
Why?
| Endovascular Procedures | 1 | 2021 | 170 | 0.740 |
Why?
| Societies, Medical | 3 | 2020 | 565 | 0.730 |
Why?
| Venous Thrombosis | 1 | 2021 | 229 | 0.730 |
Why?
| Diffusion of Innovation | 1 | 2019 | 71 | 0.720 |
Why?
| Severity of Illness Index | 10 | 2021 | 1695 | 0.720 |
Why?
| Stomach Neoplasms | 5 | 2016 | 251 | 0.710 |
Why?
| Hepatectomy | 5 | 2022 | 149 | 0.710 |
Why?
| Postoperative Hemorrhage | 3 | 2017 | 43 | 0.700 |
Why?
| Prognosis | 26 | 2016 | 3539 | 0.700 |
Why?
| CA-19-9 Antigen | 3 | 2014 | 11 | 0.690 |
Why?
| Drainage | 3 | 2015 | 141 | 0.660 |
Why?
| Cholangiocarcinoma | 4 | 2021 | 49 | 0.660 |
Why?
| Surgical Wound Infection | 3 | 2015 | 177 | 0.660 |
Why?
| Survival Rate | 24 | 2018 | 1818 | 0.650 |
Why?
| Lymph Node Excision | 8 | 2016 | 197 | 0.650 |
Why?
| Colonic Neoplasms | 9 | 2021 | 537 | 0.630 |
Why?
| Dermatitis, Atopic | 2 | 2021 | 44 | 0.630 |
Why?
| Thrombosis | 1 | 2019 | 271 | 0.620 |
Why?
| Length of Stay | 8 | 2017 | 656 | 0.620 |
Why?
| Adenocarcinoma, Mucinous | 2 | 2007 | 41 | 0.610 |
Why?
| Pancreatitis | 5 | 2015 | 83 | 0.600 |
Why?
| Preoperative Care | 8 | 2017 | 388 | 0.600 |
Why?
| Alleles | 2 | 2017 | 1083 | 0.600 |
Why?
| Education, Medical | 1 | 2019 | 215 | 0.600 |
Why?
| Learning | 1 | 2019 | 255 | 0.590 |
Why?
| Intestinal Neoplasms | 2 | 2009 | 56 | 0.580 |
Why?
| Embolization, Therapeutic | 2 | 2014 | 205 | 0.570 |
Why?
| Chemotherapy, Adjuvant | 15 | 2017 | 446 | 0.560 |
Why?
| Mass Screening | 2 | 2015 | 594 | 0.560 |
Why?
| Antimetabolites, Antineoplastic | 6 | 2018 | 235 | 0.560 |
Why?
| Mesenteric Veins | 4 | 2021 | 33 | 0.550 |
Why?
| Radiotherapy, Adjuvant | 12 | 2018 | 286 | 0.550 |
Why?
| Regional Health Planning | 2 | 2014 | 13 | 0.550 |
Why?
| Proportional Hazards Models | 11 | 2017 | 829 | 0.540 |
Why?
| Interleukin-17 | 3 | 2020 | 96 | 0.540 |
Why?
| Registries | 6 | 2017 | 654 | 0.540 |
Why?
| Hepatic Artery | 1 | 2014 | 76 | 0.530 |
Why?
| Cohort Studies | 11 | 2020 | 2587 | 0.520 |
Why?
| Cornified Envelope Proline-Rich Proteins | 1 | 2013 | 6 | 0.510 |
Why?
| Surgery, Computer-Assisted | 1 | 2015 | 98 | 0.510 |
Why?
| Carcinoma, Papillary | 4 | 2007 | 151 | 0.510 |
Why?
| Risk Factors | 21 | 2022 | 5142 | 0.510 |
Why?
| Combined Modality Therapy | 16 | 2016 | 1621 | 0.500 |
Why?
| Patient Readmission | 4 | 2017 | 293 | 0.500 |
Why?
| Databases, Factual | 10 | 2017 | 759 | 0.460 |
Why?
| Early Detection of Cancer | 2 | 2015 | 341 | 0.460 |
Why?
| Barrett Esophagus | 5 | 2018 | 91 | 0.450 |
Why?
| Quality Indicators, Health Care | 2 | 2010 | 132 | 0.450 |
Why?
| United States | 27 | 2018 | 6149 | 0.440 |
Why?
| Safety-Based Drug Withdrawals | 1 | 2011 | 2 | 0.440 |
Why?
| Radiotherapy, Conformal | 2 | 2011 | 87 | 0.430 |
Why?
| Prospective Studies | 9 | 2019 | 3933 | 0.430 |
Why?
| Multivariate Analysis | 9 | 2019 | 968 | 0.430 |
Why?
| Lymph Nodes | 7 | 2016 | 514 | 0.420 |
Why?
| Carcinoma, Hepatocellular | 3 | 2018 | 334 | 0.420 |
Why?
| Esophageal Neoplasms | 8 | 2018 | 303 | 0.410 |
Why?
| Withholding Treatment | 1 | 2011 | 109 | 0.400 |
Why?
| Carcinoid Tumor | 4 | 2002 | 41 | 0.400 |
Why?
| SEER Program | 3 | 2014 | 180 | 0.400 |
Why?
| Health Care Costs | 2 | 2017 | 229 | 0.390 |
Why?
| Follow-Up Studies | 16 | 2018 | 3575 | 0.380 |
Why?
| Quality of Health Care | 2 | 2010 | 367 | 0.380 |
Why?
| Logistic Models | 9 | 2020 | 1117 | 0.360 |
Why?
| Intestine, Small | 2 | 2009 | 297 | 0.360 |
Why?
| Pancreas | 7 | 2012 | 224 | 0.360 |
Why?
| Neoplasm, Residual | 2 | 2016 | 144 | 0.350 |
Why?
| Endoscopy, Gastrointestinal | 2 | 2018 | 150 | 0.350 |
Why?
| Hospitals, Veterans | 1 | 2007 | 17 | 0.340 |
Why?
| Angiogenesis Inhibitors | 1 | 2010 | 291 | 0.340 |
Why?
| Young Adult | 12 | 2021 | 5736 | 0.340 |
Why?
| Hospital Bed Capacity | 1 | 2007 | 19 | 0.340 |
Why?
| Age Factors | 5 | 2018 | 1800 | 0.330 |
Why?
| Neoplasms | 8 | 2022 | 2681 | 0.330 |
Why?
| Hospitals | 5 | 2019 | 213 | 0.330 |
Why?
| Incidence | 10 | 2022 | 1539 | 0.320 |
Why?
| DNA-Binding Proteins | 1 | 2013 | 1187 | 0.320 |
Why?
| Cholangitis | 1 | 2006 | 18 | 0.300 |
Why?
| Patient Selection | 4 | 2014 | 666 | 0.300 |
Why?
| Hospital Costs | 3 | 2017 | 99 | 0.300 |
Why?
| Delivery of Health Care | 1 | 2010 | 341 | 0.290 |
Why?
| Diagnostic Techniques and Procedures | 1 | 2005 | 25 | 0.290 |
Why?
| Time Factors | 9 | 2018 | 5158 | 0.290 |
Why?
| Gastrectomy | 2 | 2016 | 61 | 0.290 |
Why?
| Disposable Equipment | 2 | 2015 | 17 | 0.280 |
Why?
| Risk Assessment | 5 | 2019 | 2171 | 0.270 |
Why?
| Hospitals, Community | 3 | 2010 | 28 | 0.270 |
Why?
| Gallbladder Neoplasms | 2 | 2020 | 22 | 0.270 |
Why?
| Insurance Claim Review | 1 | 2004 | 37 | 0.260 |
Why?
| Rectum | 1 | 2004 | 152 | 0.250 |
Why?
| Esophagectomy | 3 | 2012 | 74 | 0.250 |
Why?
| Liver Transplantation | 3 | 2018 | 1241 | 0.250 |
Why?
| Drug Administration Schedule | 6 | 2017 | 932 | 0.250 |
Why?
| Rectus Abdominis | 2 | 2017 | 36 | 0.250 |
Why?
| Chemoradiotherapy | 3 | 2016 | 296 | 0.250 |
Why?
| Benzoates | 4 | 2007 | 46 | 0.240 |
Why?
| Fluorouracil | 9 | 2017 | 548 | 0.240 |
Why?
| Mortality | 1 | 2004 | 147 | 0.240 |
Why?
| Cecal Neoplasms | 1 | 2002 | 4 | 0.230 |
Why?
| Diagnosis, Differential | 6 | 2015 | 1497 | 0.230 |
Why?
| Biliary Tract Diseases | 1 | 2022 | 34 | 0.230 |
Why?
| Ileal Neoplasms | 1 | 2002 | 8 | 0.230 |
Why?
| Chronic Disease | 3 | 2020 | 940 | 0.230 |
Why?
| Neoplasm Metastasis | 5 | 2013 | 1038 | 0.230 |
Why?
| Immunosuppressive Agents | 3 | 2021 | 983 | 0.230 |
Why?
| Anus Neoplasms | 3 | 2011 | 41 | 0.230 |
Why?
| Common Bile Duct Neoplasms | 1 | 2001 | 6 | 0.230 |
Why?
| Endoscopy, Digestive System | 2 | 2012 | 66 | 0.220 |
Why?
| Bile Ducts, Extrahepatic | 2 | 2012 | 12 | 0.220 |
Why?
| Italy | 2 | 2020 | 102 | 0.220 |
Why?
| Situs Inversus | 1 | 2001 | 13 | 0.220 |
Why?
| Chemoradiotherapy, Adjuvant | 3 | 2018 | 34 | 0.220 |
Why?
| Genotype | 2 | 2017 | 1785 | 0.220 |
Why?
| Algorithms | 4 | 2018 | 1780 | 0.220 |
Why?
| Eczema | 1 | 2021 | 5 | 0.220 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2010 | 1168 | 0.210 |
Why?
| Palliative Care | 5 | 2007 | 241 | 0.210 |
Why?
| Sigmoidoscopy | 1 | 2001 | 35 | 0.210 |
Why?
| Tomography, X-Ray Computed | 8 | 2017 | 2444 | 0.210 |
Why?
| Anastomosis, Surgical | 5 | 2016 | 286 | 0.210 |
Why?
| Nurse Practitioners | 1 | 2001 | 30 | 0.210 |
Why?
| Thyroid Neoplasms | 4 | 2020 | 374 | 0.210 |
Why?
| Models, Theoretical | 1 | 2004 | 478 | 0.210 |
Why?
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 67 | 0.210 |
Why?
| Adolescent | 12 | 2021 | 8710 | 0.200 |
Why?
| Cell Cycle | 3 | 2007 | 500 | 0.200 |
Why?
| Drug Substitution | 2 | 2018 | 28 | 0.200 |
Why?
| Europe | 2 | 2019 | 300 | 0.200 |
Why?
| Genetic Markers | 3 | 2017 | 470 | 0.200 |
Why?
| Chemoembolization, Therapeutic | 4 | 2009 | 31 | 0.200 |
Why?
| Emergencies | 1 | 2020 | 106 | 0.200 |
Why?
| Drug Eruptions | 1 | 2020 | 35 | 0.200 |
Why?
| Gastrointestinal Neoplasms | 3 | 2001 | 103 | 0.200 |
Why?
| Colonic Polyps | 2 | 2008 | 126 | 0.190 |
Why?
| Personnel Selection | 1 | 2020 | 52 | 0.190 |
Why?
| Cancer Care Facilities | 2 | 2010 | 26 | 0.190 |
Why?
| Cystic Fibrosis | 1 | 2020 | 121 | 0.190 |
Why?
| Neoplasm Invasiveness | 6 | 2012 | 517 | 0.190 |
Why?
| Specialties, Surgical | 1 | 2020 | 59 | 0.190 |
Why?
| Lymphatic Metastasis | 8 | 2008 | 466 | 0.190 |
Why?
| Cell Proliferation | 6 | 2008 | 1544 | 0.190 |
Why?
| Fellowships and Scholarships | 1 | 2020 | 96 | 0.190 |
Why?
| Arachidonate 5-Lipoxygenase | 3 | 2008 | 22 | 0.180 |
Why?
| Interviews as Topic | 1 | 2020 | 314 | 0.180 |
Why?
| Kaplan-Meier Estimate | 5 | 2018 | 847 | 0.180 |
Why?
| User-Computer Interface | 1 | 2020 | 184 | 0.180 |
Why?
| Yttrium Radioisotopes | 2 | 2009 | 29 | 0.180 |
Why?
| Neoplasm Recurrence, Local | 6 | 2014 | 1223 | 0.180 |
Why?
| Propensity Score | 4 | 2020 | 136 | 0.180 |
Why?
| Adenoma | 3 | 2008 | 232 | 0.180 |
Why?
| Education, Medical, Continuing | 2 | 2015 | 103 | 0.170 |
Why?
| Carcinoma, Ductal, Breast | 2 | 1997 | 154 | 0.170 |
Why?
| Comorbidity | 3 | 2021 | 919 | 0.170 |
Why?
| Radiotherapy | 4 | 2012 | 325 | 0.170 |
Why?
| Thyroidectomy | 3 | 2007 | 162 | 0.170 |
Why?
| Reoperation | 3 | 2017 | 571 | 0.170 |
Why?
| Carcinoma in Situ | 2 | 2005 | 52 | 0.170 |
Why?
| Gene Expression Profiling | 3 | 2018 | 1325 | 0.170 |
Why?
| Gene Amplification | 1 | 2018 | 128 | 0.170 |
Why?
| Liver | 2 | 2017 | 1199 | 0.170 |
Why?
| Databases as Topic | 2 | 2007 | 90 | 0.170 |
Why?
| Stromal Cells | 2 | 2015 | 119 | 0.160 |
Why?
| Receptors, Calcitriol | 1 | 2018 | 129 | 0.160 |
Why?
| Laparotomy | 1 | 2017 | 53 | 0.160 |
Why?
| Evidence-Based Medicine | 1 | 2020 | 423 | 0.160 |
Why?
| Nuclear Proteins | 2 | 1999 | 683 | 0.160 |
Why?
| Receptors, Interleukin-17 | 1 | 2016 | 10 | 0.160 |
Why?
| Predictive Value of Tests | 5 | 2014 | 1622 | 0.160 |
Why?
| Incidental Findings | 1 | 2017 | 90 | 0.160 |
Why?
| Abdominal Wall | 1 | 2017 | 29 | 0.160 |
Why?
| Dyslipidemias | 1 | 2018 | 106 | 0.160 |
Why?
| Pylorus | 2 | 2007 | 22 | 0.160 |
Why?
| Muscular Atrophy | 1 | 2017 | 38 | 0.160 |
Why?
| Longitudinal Studies | 2 | 2018 | 950 | 0.160 |
Why?
| Stomach | 2 | 2012 | 109 | 0.160 |
Why?
| Skin | 2 | 2020 | 540 | 0.160 |
Why?
| Proto-Oncogene Proteins pp60(c-src) | 2 | 1993 | 12 | 0.150 |
Why?
| Electric Impedance | 1 | 2016 | 102 | 0.150 |
Why?
| Vascular Surgical Procedures | 1 | 2017 | 147 | 0.150 |
Why?
| Antineoplastic Agents | 4 | 2016 | 2281 | 0.150 |
Why?
| Guideline Adherence | 4 | 2017 | 216 | 0.150 |
Why?
| Disease-Free Survival | 4 | 2017 | 1183 | 0.150 |
Why?
| Tetradecanoylphorbol Acetate | 2 | 2006 | 137 | 0.150 |
Why?
| Cell Line, Tumor | 10 | 2018 | 2329 | 0.150 |
Why?
| Gastroesophageal Reflux | 2 | 2015 | 106 | 0.150 |
Why?
| Mutation | 3 | 2018 | 3768 | 0.140 |
Why?
| Drug Resistance | 1 | 2016 | 262 | 0.140 |
Why?
| Lymphoma | 2 | 2002 | 258 | 0.140 |
Why?
| Benchmarking | 2 | 2008 | 58 | 0.140 |
Why?
| Academic Medical Centers | 2 | 2007 | 356 | 0.140 |
Why?
| Feasibility Studies | 4 | 2016 | 721 | 0.140 |
Why?
| Coronavirus Infections | 1 | 2020 | 283 | 0.140 |
Why?
| Pneumonia, Viral | 1 | 2020 | 302 | 0.140 |
Why?
| Cell Division | 6 | 2007 | 705 | 0.140 |
Why?
| Remission, Spontaneous | 1 | 2014 | 52 | 0.130 |
Why?
| Membrane Proteins | 4 | 2005 | 1169 | 0.130 |
Why?
| Cholecystectomy, Laparoscopic | 1 | 2014 | 47 | 0.130 |
Why?
| Herniorrhaphy | 1 | 2015 | 71 | 0.130 |
Why?
| Hernia, Inguinal | 1 | 2015 | 64 | 0.130 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2005 | 220 | 0.130 |
Why?
| Gene Frequency | 1 | 2016 | 650 | 0.130 |
Why?
| Genetic Predisposition to Disease | 3 | 2018 | 2171 | 0.130 |
Why?
| Operating Rooms | 1 | 2014 | 119 | 0.130 |
Why?
| Magnetic Resonance Imaging | 4 | 2015 | 3089 | 0.120 |
Why?
| Quality Improvement | 1 | 2017 | 366 | 0.120 |
Why?
| Neutropenia | 2 | 2011 | 212 | 0.120 |
Why?
| Cost-Benefit Analysis | 3 | 2017 | 425 | 0.120 |
Why?
| Trisaccharides | 1 | 2012 | 12 | 0.120 |
Why?
| Immunotherapy, Active | 1 | 2012 | 15 | 0.120 |
Why?
| Interleukin-23 | 1 | 2013 | 56 | 0.120 |
Why?
| Internship and Residency | 1 | 2022 | 920 | 0.120 |
Why?
| Interleukin-12 | 1 | 2013 | 109 | 0.120 |
Why?
| Urinary Bladder Neoplasms | 2 | 1993 | 349 | 0.120 |
Why?
| Hemorrhage | 1 | 2014 | 236 | 0.120 |
Why?
| Quality Control | 1 | 2012 | 112 | 0.120 |
Why?
| Radiopharmaceuticals | 2 | 2012 | 157 | 0.120 |
Why?
| Jaundice, Obstructive | 1 | 2012 | 10 | 0.120 |
Why?
| Gallbladder | 1 | 2012 | 26 | 0.120 |
Why?
| Arthritis, Psoriatic | 1 | 2012 | 29 | 0.120 |
Why?
| Adipocytes, White | 1 | 2012 | 2 | 0.120 |
Why?
| Ischemic Preconditioning | 1 | 2012 | 37 | 0.110 |
Why?
| Nausea | 2 | 2011 | 169 | 0.110 |
Why?
| Bile Ducts, Intrahepatic | 1 | 2012 | 51 | 0.110 |
Why?
| Electroporation | 1 | 2012 | 56 | 0.110 |
Why?
| Practice Guidelines as Topic | 1 | 2020 | 1032 | 0.110 |
Why?
| Serpins | 1 | 2012 | 26 | 0.110 |
Why?
| Organoplatinum Compounds | 3 | 2017 | 95 | 0.110 |
Why?
| Gene Deletion | 1 | 2013 | 328 | 0.110 |
Why?
| Leucovorin | 3 | 2017 | 219 | 0.110 |
Why?
| Ablation Techniques | 1 | 2012 | 30 | 0.110 |
Why?
| Protein-Tyrosine Kinases | 2 | 1993 | 300 | 0.110 |
Why?
| Nerve Growth Factors | 1 | 2012 | 60 | 0.110 |
Why?
| Spectrum Analysis | 1 | 2012 | 120 | 0.110 |
Why?
| Esophagus | 1 | 2012 | 102 | 0.110 |
Why?
| Sex Factors | 4 | 2014 | 1020 | 0.110 |
Why?
| Radiology, Interventional | 1 | 2012 | 69 | 0.110 |
Why?
| Ultrasonography, Interventional | 1 | 2012 | 106 | 0.110 |
Why?
| Lipoxygenase Inhibitors | 2 | 2008 | 33 | 0.110 |
Why?
| Microspheres | 2 | 2009 | 89 | 0.110 |
Why?
| Photochemotherapy | 1 | 2012 | 93 | 0.110 |
Why?
| Arteries | 1 | 2012 | 176 | 0.110 |
Why?
| Disease Progression | 5 | 2018 | 1431 | 0.110 |
Why?
| Cancer Vaccines | 1 | 2012 | 152 | 0.110 |
Why?
| Leukopenia | 1 | 2011 | 65 | 0.110 |
Why?
| Ileus | 1 | 2011 | 13 | 0.110 |
Why?
| Abdominal Abscess | 1 | 2011 | 18 | 0.110 |
Why?
| Camptothecin | 3 | 2017 | 194 | 0.110 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 140 | 0.110 |
Why?
| Brachytherapy | 1 | 2012 | 116 | 0.110 |
Why?
| Clinical Trials as Topic | 1 | 2016 | 1150 | 0.110 |
Why?
| Appointments and Schedules | 1 | 2011 | 35 | 0.100 |
Why?
| Biopsy | 5 | 2009 | 1123 | 0.100 |
Why?
| Receptors, Leukotriene B4 | 2 | 2007 | 4 | 0.100 |
Why?
| Endoscopy | 2 | 2022 | 314 | 0.100 |
Why?
| Chromosome Aberrations | 1 | 2012 | 381 | 0.100 |
Why?
| Methotrexate | 1 | 2011 | 247 | 0.100 |
Why?
| Treatment Failure | 2 | 2009 | 281 | 0.100 |
Why?
| Immunohistochemistry | 9 | 2009 | 1725 | 0.100 |
Why?
| Health Services Needs and Demand | 1 | 2011 | 95 | 0.100 |
Why?
| G2 Phase | 2 | 2006 | 32 | 0.100 |
Why?
| Intestinal Obstruction | 1 | 2011 | 91 | 0.100 |
Why?
| Mucin 5AC | 1 | 2009 | 8 | 0.100 |
Why?
| Mucin-2 | 1 | 2009 | 13 | 0.100 |
Why?
| Cyclosporine | 1 | 2011 | 241 | 0.100 |
Why?
| Waiting Lists | 1 | 2011 | 149 | 0.100 |
Why?
| Mucin-1 | 1 | 2009 | 45 | 0.100 |
Why?
| Pancreatic Ducts | 2 | 1999 | 24 | 0.100 |
Why?
| Learning Curve | 2 | 2022 | 18 | 0.100 |
Why?
| Spleen | 1 | 2011 | 438 | 0.100 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 244 | 0.100 |
Why?
| Sarcoma | 2 | 2002 | 204 | 0.100 |
Why?
| Pancreatitis, Chronic | 1 | 2010 | 47 | 0.100 |
Why?
| Adrenal Cortex Hormones | 1 | 2021 | 253 | 0.100 |
Why?
| Duodenal Neoplasms | 1 | 2009 | 19 | 0.100 |
Why?
| Safety | 2 | 2010 | 157 | 0.090 |
Why?
| Remission Induction | 1 | 2011 | 707 | 0.090 |
Why?
| Maximum Tolerated Dose | 2 | 2010 | 269 | 0.090 |
Why?
| Illinois | 3 | 2015 | 450 | 0.090 |
Why?
| Polymorphism, Genetic | 1 | 2013 | 798 | 0.090 |
Why?
| Vitamin D | 3 | 2018 | 261 | 0.090 |
Why?
| Hypertension | 1 | 2018 | 1201 | 0.090 |
Why?
| Breast Neoplasms | 3 | 1999 | 2738 | 0.090 |
Why?
| DNA Methylation | 3 | 2010 | 585 | 0.090 |
Why?
| Ischemia | 1 | 2011 | 242 | 0.090 |
Why?
| Radiotherapy Dosage | 2 | 2011 | 481 | 0.090 |
Why?
| Carcinoma, Acinar Cell | 1 | 2008 | 11 | 0.090 |
Why?
| S Phase | 2 | 2007 | 61 | 0.090 |
Why?
| Research Design | 3 | 2009 | 566 | 0.090 |
Why?
| Hepatocyte Nuclear Factor 1-beta | 1 | 2008 | 34 | 0.090 |
Why?
| Animals | 11 | 2016 | 25816 | 0.090 |
Why?
| Chicago | 2 | 2020 | 1339 | 0.090 |
Why?
| Socioeconomic Factors | 2 | 2008 | 537 | 0.090 |
Why?
| Neoplasms, Squamous Cell | 1 | 2008 | 20 | 0.090 |
Why?
| Esophagogastric Junction | 1 | 2008 | 31 | 0.090 |
Why?
| Gastroscopy | 1 | 2007 | 22 | 0.090 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2008 | 55 | 0.090 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2008 | 59 | 0.090 |
Why?
| Gastrointestinal Stromal Tumors | 1 | 2007 | 22 | 0.090 |
Why?
| Diagnostic Imaging | 1 | 2012 | 448 | 0.080 |
Why?
| Catheter Ablation | 1 | 2010 | 217 | 0.080 |
Why?
| Apoptosis | 4 | 2008 | 1654 | 0.080 |
Why?
| Leukotriene Antagonists | 1 | 2007 | 25 | 0.080 |
Why?
| Apigenin | 1 | 2006 | 7 | 0.080 |
Why?
| Hemothorax | 1 | 1987 | 13 | 0.080 |
Why?
| Referral and Consultation | 1 | 2010 | 306 | 0.080 |
Why?
| Stilbenes | 1 | 2007 | 23 | 0.080 |
Why?
| MicroRNAs | 1 | 2012 | 509 | 0.080 |
Why?
| Hospitals, Teaching | 1 | 2007 | 113 | 0.080 |
Why?
| Disease Models, Animal | 2 | 2008 | 2186 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 4 | 2006 | 1972 | 0.080 |
Why?
| Adenoma, Islet Cell | 2 | 2007 | 27 | 0.080 |
Why?
| Quality Assurance, Health Care | 1 | 2008 | 223 | 0.080 |
Why?
| Mitosis | 1 | 2006 | 147 | 0.080 |
Why?
| Guidelines as Topic | 1 | 2007 | 159 | 0.080 |
Why?
| Bone Morphogenetic Proteins | 1 | 2007 | 127 | 0.080 |
Why?
| Leukotriene B4 | 1 | 2005 | 12 | 0.070 |
Why?
| Depsipeptides | 1 | 2006 | 29 | 0.070 |
Why?
| Neoplasm Seeding | 1 | 2005 | 17 | 0.070 |
Why?
| Patient Compliance | 1 | 2007 | 223 | 0.070 |
Why?
| Ultrasonography | 2 | 2012 | 656 | 0.070 |
Why?
| Epithelium | 1 | 2006 | 312 | 0.070 |
Why?
| Surgical Flaps | 1 | 2008 | 249 | 0.070 |
Why?
| Cystadenocarcinoma | 2 | 1995 | 12 | 0.070 |
Why?
| Odds Ratio | 1 | 2007 | 648 | 0.070 |
Why?
| Postoperative Care | 2 | 2017 | 206 | 0.070 |
Why?
| Bariatric Surgery | 1 | 2008 | 186 | 0.070 |
Why?
| Cyclooxygenase 2 | 1 | 2005 | 99 | 0.070 |
Why?
| Phosphorylation | 4 | 2006 | 1099 | 0.070 |
Why?
| Blotting, Western | 4 | 2012 | 778 | 0.070 |
Why?
| Reference Values | 2 | 1999 | 656 | 0.070 |
Why?
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 16 | 0.070 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 182 | 0.070 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 284 | 0.070 |
Why?
| Diagnostic Errors | 1 | 2006 | 157 | 0.070 |
Why?
| Actuarial Analysis | 2 | 2002 | 66 | 0.070 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 240 | 0.070 |
Why?
| Drug Synergism | 1 | 2005 | 305 | 0.070 |
Why?
| Reconstructive Surgical Procedures | 1 | 2008 | 262 | 0.070 |
Why?
| Pilot Projects | 2 | 2017 | 802 | 0.070 |
Why?
| Infusions, Intra-Arterial | 2 | 2008 | 27 | 0.070 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 211 | 0.070 |
Why?
| Fatal Outcome | 1 | 2004 | 285 | 0.070 |
Why?
| Melanoma | 1 | 2008 | 430 | 0.060 |
Why?
| Soft Tissue Neoplasms | 1 | 2004 | 125 | 0.060 |
Why?
| RNA, Messenger | 4 | 2018 | 1936 | 0.060 |
Why?
| Skin Neoplasms | 1 | 2008 | 512 | 0.060 |
Why?
| Demography | 1 | 2004 | 159 | 0.060 |
Why?
| Radiography | 1 | 2005 | 806 | 0.060 |
Why?
| Social Class | 1 | 2004 | 122 | 0.060 |
Why?
| Capillaries | 1 | 2003 | 90 | 0.060 |
Why?
| Protein Kinases | 2 | 1996 | 207 | 0.060 |
Why?
| Case-Control Studies | 2 | 2006 | 1735 | 0.060 |
Why?
| Cyclin A | 3 | 2007 | 28 | 0.060 |
Why?
| Hyperparathyroidism | 1 | 2002 | 67 | 0.060 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2022 | 28 | 0.060 |
Why?
| Parathyroid Neoplasms | 1 | 2002 | 52 | 0.060 |
Why?
| Colectomy | 3 | 2008 | 174 | 0.060 |
Why?
| Carcinoembryonic Antigen | 2 | 1999 | 37 | 0.060 |
Why?
| Parathyroidectomy | 1 | 2002 | 73 | 0.060 |
Why?
| Bile | 1 | 2022 | 54 | 0.060 |
Why?
| Immunoenzyme Techniques | 3 | 2008 | 301 | 0.060 |
Why?
| Cadherins | 1 | 2002 | 147 | 0.060 |
Why?
| Cardiac Surgical Procedures | 1 | 1987 | 447 | 0.060 |
Why?
| Regression Analysis | 2 | 2017 | 591 | 0.060 |
Why?
| Bone Neoplasms | 1 | 2004 | 319 | 0.060 |
Why?
| Biopsy, Needle | 2 | 2009 | 234 | 0.060 |
Why?
| Thymidylate Synthase | 1 | 2001 | 13 | 0.060 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2001 | 59 | 0.050 |
Why?
| Cell Cycle Proteins | 2 | 2006 | 375 | 0.050 |
Why?
| Outpatient Clinics, Hospital | 1 | 2001 | 22 | 0.050 |
Why?
| Credentialing | 1 | 2001 | 15 | 0.050 |
Why?
| Marketing of Health Services | 1 | 2001 | 14 | 0.050 |
Why?
| DNA, Neoplasm | 2 | 2006 | 266 | 0.050 |
Why?
| Midwestern United States | 1 | 2001 | 74 | 0.050 |
Why?
| Clinical Competence | 2 | 2022 | 715 | 0.050 |
Why?
| Cisplatin | 3 | 2011 | 586 | 0.050 |
Why?
| Biological Specimen Banks | 1 | 2020 | 52 | 0.050 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2000 | 190 | 0.050 |
Why?
| Neovascularization, Pathologic | 1 | 2002 | 337 | 0.050 |
Why?
| Surgical Procedures, Operative | 2 | 2011 | 167 | 0.050 |
Why?
| Sequence Deletion | 1 | 2020 | 206 | 0.050 |
Why?
| Sensitivity and Specificity | 2 | 2009 | 1943 | 0.050 |
Why?
| Florida | 1 | 2020 | 50 | 0.050 |
Why?
| Leiomyomatosis | 1 | 2000 | 12 | 0.050 |
Why?
| Morbidity | 1 | 2020 | 139 | 0.050 |
Why?
| Pharyngeal Neoplasms | 1 | 1999 | 13 | 0.050 |
Why?
| Untranslated Regions | 1 | 2019 | 19 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2000 | 434 | 0.050 |
Why?
| Nuclear Matrix-Associated Proteins | 1 | 1999 | 13 | 0.050 |
Why?
| Bronchi | 1 | 2020 | 227 | 0.050 |
Why?
| Antigens, Nuclear | 1 | 1999 | 25 | 0.050 |
Why?
| Reagent Kits, Diagnostic | 1 | 1999 | 36 | 0.050 |
Why?
| ROC Curve | 2 | 2014 | 736 | 0.050 |
Why?
| Anticoagulants | 1 | 2022 | 385 | 0.050 |
Why?
| Adenomatous Polyposis Coli | 1 | 1999 | 43 | 0.050 |
Why?
| Open Reading Frames | 1 | 2019 | 119 | 0.050 |
Why?
| Congresses as Topic | 1 | 2020 | 117 | 0.050 |
Why?
| Immunoassay | 1 | 1999 | 89 | 0.050 |
Why?
| Steroids | 1 | 2020 | 167 | 0.050 |
Why?
| Genetic Counseling | 1 | 1999 | 92 | 0.050 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2001 | 361 | 0.050 |
Why?
| Program Evaluation | 1 | 2020 | 287 | 0.040 |
Why?
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 8 | 0.040 |
Why?
| Autoantigens | 1 | 1999 | 129 | 0.040 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2020 | 256 | 0.040 |
Why?
| Statistics, Nonparametric | 2 | 2009 | 303 | 0.040 |
Why?
| Chi-Square Distribution | 2 | 2009 | 359 | 0.040 |
Why?
| Intention to Treat Analysis | 1 | 2018 | 67 | 0.040 |
Why?
| Cryosurgery | 1 | 1998 | 33 | 0.040 |
Why?
| Flow Cytometry | 3 | 2007 | 683 | 0.040 |
Why?
| Receptor, Notch1 | 1 | 2018 | 81 | 0.040 |
Why?
| Gastrointestinal Diseases | 1 | 1999 | 143 | 0.040 |
Why?
| Curriculum | 1 | 2022 | 483 | 0.040 |
Why?
| Tumor Cells, Cultured | 3 | 2008 | 1039 | 0.040 |
Why?
| Radiography, Abdominal | 1 | 2017 | 68 | 0.040 |
Why?
| Hernia, Ventral | 1 | 2017 | 24 | 0.040 |
Why?
| Neoplasms, Second Primary | 1 | 2000 | 244 | 0.040 |
Why?
| Prolactinoma | 1 | 1997 | 8 | 0.040 |
Why?
| Nucleic Acid Synthesis Inhibitors | 2 | 2007 | 16 | 0.040 |
Why?
| Blood Loss, Surgical | 1 | 2017 | 106 | 0.040 |
Why?
| Shock, Septic | 1 | 2017 | 79 | 0.040 |
Why?
| Atrophy | 1 | 2017 | 75 | 0.040 |
Why?
| Cyclin E | 2 | 2007 | 27 | 0.040 |
Why?
| Cyclin B | 2 | 2006 | 16 | 0.040 |
Why?
| Genetic Engineering | 1 | 1997 | 108 | 0.040 |
Why?
| Animals, Genetically Modified | 1 | 1997 | 180 | 0.040 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 1998 | 170 | 0.040 |
Why?
| Breast Neoplasms, Male | 1 | 1997 | 29 | 0.040 |
Why?
| Blood Transfusion | 1 | 2017 | 150 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 869 | 0.040 |
Why?
| Serum Albumin | 1 | 2017 | 132 | 0.040 |
Why?
| Models, Economic | 1 | 2017 | 60 | 0.040 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 73 | 0.040 |
Why?
| Pituitary Neoplasms | 1 | 1997 | 64 | 0.040 |
Why?
| Body Composition | 1 | 2016 | 65 | 0.040 |
Why?
| Neoplasms, Multiple Primary | 1 | 1997 | 101 | 0.040 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2018 | 374 | 0.040 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 679 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 1999 | 918 | 0.040 |
Why?
| Data Collection | 1 | 2017 | 357 | 0.040 |
Why?
| Molecular Sequence Data | 4 | 2005 | 3051 | 0.040 |
Why?
| Cystadenoma, Mucinous | 1 | 1995 | 7 | 0.040 |
Why?
| Cystadenoma, Serous | 1 | 1995 | 15 | 0.040 |
Why?
| Butadienes | 2 | 2005 | 33 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 907 | 0.040 |
Why?
| RNA Helicases | 1 | 1996 | 34 | 0.040 |
Why?
| Flavonoids | 2 | 2006 | 84 | 0.040 |
Why?
| Mice | 5 | 2012 | 10840 | 0.040 |
Why?
| Genetic Heterogeneity | 1 | 2015 | 60 | 0.040 |
Why?
| Cost Control | 1 | 2015 | 44 | 0.040 |
Why?
| Genes, Tumor Suppressor | 1 | 1996 | 157 | 0.040 |
Why?
| Nitriles | 2 | 2005 | 140 | 0.040 |
Why?
| Keratin-19 | 1 | 2014 | 9 | 0.040 |
Why?
| Mice, Nude | 2 | 2008 | 764 | 0.030 |
Why?
| Cystadenoma | 1 | 1994 | 19 | 0.030 |
Why?
| Polyethylene Glycols | 1 | 2017 | 362 | 0.030 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 33 | 0.030 |
Why?
| Ki-67 Antigen | 1 | 2014 | 57 | 0.030 |
Why?
| Proton Pump Inhibitors | 1 | 2015 | 33 | 0.030 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 181 | 0.030 |
Why?
| Neoplasm Regression, Spontaneous | 1 | 2014 | 6 | 0.030 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 79 | 0.030 |
Why?
| Patient Care Planning | 1 | 2015 | 80 | 0.030 |
Why?
| Perioperative Care | 1 | 2016 | 151 | 0.030 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2015 | 160 | 0.030 |
Why?
| Pandemics | 1 | 2020 | 603 | 0.030 |
Why?
| Surgical Mesh | 1 | 2015 | 85 | 0.030 |
Why?
| Mastectomy | 1 | 1996 | 222 | 0.030 |
Why?
| Adipose Tissue | 1 | 2016 | 238 | 0.030 |
Why?
| Gene Expression | 2 | 2015 | 1280 | 0.030 |
Why?
| Postoperative Period | 1 | 2014 | 295 | 0.030 |
Why?
| Breast | 1 | 1996 | 273 | 0.030 |
Why?
| Double-Blind Method | 1 | 2018 | 1798 | 0.030 |
Why?
| Bone Density Conservation Agents | 1 | 2014 | 46 | 0.030 |
Why?
| DNA | 2 | 2010 | 1252 | 0.030 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 250 | 0.030 |
Why?
| Phosphopyruvate Hydratase | 1 | 1993 | 40 | 0.030 |
Why?
| Mammography | 1 | 1996 | 452 | 0.030 |
Why?
| Body Mass Index | 1 | 2016 | 740 | 0.030 |
Why?
| Antigen-Antibody Complex | 1 | 1993 | 87 | 0.030 |
Why?
| Jejunostomy | 1 | 2012 | 14 | 0.030 |
Why?
| Gastric Emptying | 1 | 2012 | 22 | 0.030 |
Why?
| Ligation | 1 | 2012 | 52 | 0.030 |
Why?
| Blood Sedimentation | 1 | 2012 | 14 | 0.030 |
Why?
| Synovial Membrane | 1 | 2012 | 27 | 0.030 |
Why?
| Celiac Artery | 1 | 2012 | 21 | 0.030 |
Why?
| Population Surveillance | 1 | 2014 | 220 | 0.030 |
Why?
| Cell Transformation, Neoplastic | 1 | 2015 | 405 | 0.030 |
Why?
| Immunoblotting | 1 | 1993 | 266 | 0.030 |
Why?
| Analysis of Variance | 1 | 2014 | 900 | 0.030 |
Why?
| Bone Resorption | 1 | 2012 | 42 | 0.030 |
Why?
| Genetic Variation | 1 | 2019 | 1322 | 0.030 |
Why?
| Enteral Nutrition | 1 | 2012 | 98 | 0.030 |
Why?
| Rats | 3 | 2005 | 3940 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2012 | 42 | 0.030 |
Why?
| Rats, Sprague-Dawley | 2 | 2005 | 1199 | 0.030 |
Why?
| Cricetinae | 2 | 2005 | 561 | 0.030 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2012 | 70 | 0.030 |
Why?
| Adiposity | 1 | 2012 | 67 | 0.030 |
Why?
| Constriction, Pathologic | 1 | 2012 | 201 | 0.030 |
Why?
| Mitomycin | 1 | 2011 | 31 | 0.030 |
Why?
| C-Reactive Protein | 1 | 2012 | 183 | 0.030 |
Why?
| Anastomotic Leak | 1 | 2012 | 101 | 0.030 |
Why?
| Benzodiazepines | 1 | 2011 | 62 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2015 | 812 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 266 | 0.030 |
Why?
| Eye Proteins | 1 | 2012 | 122 | 0.030 |
Why?
| Genome-Wide Association Study | 1 | 2018 | 1508 | 0.030 |
Why?
| Validation Studies as Topic | 1 | 2010 | 15 | 0.030 |
Why?
| Intestinal Perforation | 1 | 1990 | 34 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2010 | 120 | 0.020 |
Why?
| Health Care Surveys | 1 | 2011 | 275 | 0.020 |
Why?
| Metaplasia | 1 | 2009 | 36 | 0.020 |
Why?
| Sphincterotomy, Endoscopic | 1 | 2009 | 9 | 0.020 |
Why?
| Forecasting | 1 | 2011 | 306 | 0.020 |
Why?
| Obesity | 1 | 2016 | 919 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2018 | 2275 | 0.020 |
Why?
| Cause of Death | 1 | 2010 | 273 | 0.020 |
Why?
| Receptors, Androgen | 1 | 2009 | 90 | 0.020 |
Why?
| Quality of Life | 1 | 2017 | 1387 | 0.020 |
Why?
| Radiation Injuries | 1 | 1990 | 158 | 0.020 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2009 | 84 | 0.020 |
Why?
| Thymidine | 1 | 2008 | 58 | 0.020 |
Why?
| Microarray Analysis | 1 | 2009 | 93 | 0.020 |
Why?
| Periodic Acid-Schiff Reaction | 1 | 2008 | 6 | 0.020 |
Why?
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 10 | 0.020 |
Why?
| Pelvic Exenteration | 1 | 2008 | 5 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2010 | 297 | 0.020 |
Why?
| Perineum | 1 | 2008 | 23 | 0.020 |
Why?
| Intestinal Fistula | 1 | 2008 | 30 | 0.020 |
Why?
| Probability | 1 | 2009 | 345 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2020 | 2145 | 0.020 |
Why?
| Amino Acid Sequence | 2 | 2005 | 2077 | 0.020 |
Why?
| Abdominal Cavity | 1 | 2008 | 14 | 0.020 |
Why?
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2007 | 11 | 0.020 |
Why?
| Professional Practice | 1 | 2008 | 43 | 0.020 |
Why?
| Tomography, Emission-Computed | 1 | 2008 | 104 | 0.020 |
Why?
| Gastrointestinal Hemorrhage | 1 | 1990 | 216 | 0.020 |
Why?
| Gastric Outlet Obstruction | 1 | 2007 | 11 | 0.020 |
Why?
| Mice, Transgenic | 2 | 2005 | 1514 | 0.020 |
Why?
| Hospital Mortality | 1 | 2010 | 323 | 0.020 |
Why?
| Genes, bcl-2 | 1 | 2007 | 17 | 0.020 |
Why?
| Caspase 7 | 1 | 2007 | 15 | 0.020 |
Why?
| Cytochromes c | 1 | 2007 | 27 | 0.020 |
Why?
| Cyclin-Dependent Kinase 2 | 1 | 2007 | 23 | 0.020 |
Why?
| Cholestasis | 1 | 2007 | 44 | 0.020 |
Why?
| Caspase 9 | 1 | 2007 | 47 | 0.020 |
Why?
| Asthenia | 1 | 2007 | 4 | 0.020 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 35 | 0.020 |
Why?
| bcl-2-Associated X Protein | 1 | 2007 | 46 | 0.020 |
Why?
| Vagina | 1 | 2008 | 102 | 0.020 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 44 | 0.020 |
Why?
| Growth Differentiation Factor 15 | 1 | 2007 | 9 | 0.020 |
Why?
| Dactinomycin | 1 | 2007 | 35 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 1993 | 801 | 0.020 |
Why?
| cdc25 Phosphatases | 1 | 2006 | 17 | 0.020 |
Why?
| Surgical Wound Dehiscence | 1 | 1987 | 34 | 0.020 |
Why?
| Workload | 1 | 2008 | 125 | 0.020 |
Why?
| Caspase 3 | 1 | 2007 | 160 | 0.020 |
Why?
| Immunoglobulin G | 1 | 2009 | 446 | 0.020 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2008 | 442 | 0.020 |
Why?
| CDC2 Protein Kinase | 1 | 2006 | 44 | 0.020 |
Why?
| Headache | 1 | 2007 | 66 | 0.020 |
Why?
| Cyclin B1 | 1 | 2006 | 16 | 0.020 |
Why?
| Maleimides | 1 | 2006 | 29 | 0.020 |
Why?
| Mice, Knockout | 1 | 2012 | 1909 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 68 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 74 | 0.020 |
Why?
| MAP Kinase Kinase Kinases | 1 | 2006 | 41 | 0.020 |
Why?
| Vomiting | 1 | 2008 | 182 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2008 | 1040 | 0.020 |
Why?
| Positron-Emission Tomography | 1 | 2007 | 273 | 0.020 |
Why?
| Nitrobenzenes | 1 | 2005 | 11 | 0.020 |
Why?
| Cell Nucleus | 1 | 2008 | 572 | 0.020 |
Why?
| Nitrosamines | 1 | 2005 | 8 | 0.020 |
Why?
| Enzyme Activation | 1 | 2007 | 692 | 0.020 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 35 | 0.020 |
Why?
| Cell Growth Processes | 1 | 2005 | 79 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 275 | 0.020 |
Why?
| Obesity, Morbid | 1 | 2008 | 204 | 0.020 |
Why?
| Androstadienes | 1 | 2005 | 72 | 0.020 |
Why?
| NIH 3T3 Cells | 1 | 2005 | 104 | 0.020 |
Why?
| Protein Kinase C | 1 | 2006 | 270 | 0.020 |
Why?
| Culture Media, Conditioned | 1 | 2005 | 100 | 0.020 |
Why?
| Coculture Techniques | 1 | 2005 | 155 | 0.020 |
Why?
| Base Sequence | 2 | 1999 | 2326 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2009 | 679 | 0.020 |
Why?
| Disease Management | 1 | 2007 | 324 | 0.020 |
Why?
| PPAR gamma | 1 | 2005 | 63 | 0.020 |
Why?
| Carcinogens | 1 | 2005 | 108 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2007 | 539 | 0.020 |
Why?
| Transfection | 1 | 2007 | 892 | 0.020 |
Why?
| Quinolines | 1 | 2005 | 90 | 0.020 |
Why?
| Random Allocation | 1 | 2005 | 335 | 0.020 |
Why?
| Neoplasm Transplantation | 1 | 2005 | 388 | 0.020 |
Why?
| Indoles | 1 | 2006 | 317 | 0.020 |
Why?
| Sequence Homology, Amino Acid | 1 | 2005 | 418 | 0.020 |
Why?
| Green Fluorescent Proteins | 1 | 2005 | 296 | 0.020 |
Why?
| Signal Transduction | 2 | 2005 | 3162 | 0.020 |
Why?
| Up-Regulation | 1 | 2007 | 693 | 0.020 |
Why?
| Pregnancy Complications | 1 | 2007 | 328 | 0.020 |
Why?
| Neoplasm Proteins | 1 | 2007 | 531 | 0.020 |
Why?
| Administration, Oral | 1 | 2005 | 689 | 0.020 |
Why?
| Sulfonamides | 1 | 2005 | 297 | 0.020 |
Why?
| Cell Survival | 1 | 2006 | 958 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2005 | 630 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2007 | 1119 | 0.010 |
Why?
| Protein Kinase Inhibitors | 1 | 2006 | 556 | 0.010 |
Why?
| Thyroid Gland | 1 | 2002 | 265 | 0.010 |
Why?
| Cell Line | 1 | 2006 | 2474 | 0.010 |
Why?
| Cell Differentiation | 1 | 2007 | 1424 | 0.010 |
Why?
| Vulvar Neoplasms | 1 | 2000 | 19 | 0.010 |
Why?
| Pregnancy | 1 | 2007 | 2707 | 0.010 |
Why?
| Technetium Tc 99m Sulfur Colloid | 1 | 1999 | 10 | 0.010 |
Why?
| Palpation | 1 | 1999 | 18 | 0.010 |
Why?
| Cells, Cultured | 1 | 2005 | 2796 | 0.010 |
Why?
| Coloring Agents | 1 | 1999 | 65 | 0.010 |
Why?
| Protein Isoforms | 1 | 2000 | 259 | 0.010 |
Why?
| Introns | 1 | 2000 | 283 | 0.010 |
Why?
| Blotting, Northern | 1 | 1999 | 256 | 0.010 |
Why?
| Axilla | 1 | 1999 | 92 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1999 | 217 | 0.010 |
Why?
| Exons | 1 | 2000 | 441 | 0.010 |
Why?
| Image Processing, Computer-Assisted | 1 | 2005 | 1158 | 0.010 |
Why?
| Medical Staff, Hospital | 1 | 1999 | 108 | 0.010 |
Why?
| Heart Failure | 1 | 2007 | 1090 | 0.010 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 64 | 0.010 |
Why?
| Gynecomastia | 1 | 1997 | 8 | 0.010 |
Why?
| Mastectomy, Modified Radical | 1 | 1997 | 6 | 0.010 |
Why?
| Genetic Techniques | 1 | 1997 | 70 | 0.010 |
Why?
| Microscopy, Electron | 1 | 1997 | 523 | 0.010 |
Why?
| Recurrence | 1 | 1999 | 1113 | 0.010 |
Why?
| RNA, Double-Stranded | 1 | 1996 | 22 | 0.010 |
Why?
| Hyperplasia | 1 | 1996 | 142 | 0.010 |
Why?
| DEAD-box RNA Helicases | 1 | 1996 | 57 | 0.010 |
Why?
| eIF-2 Kinase | 1 | 1995 | 46 | 0.010 |
Why?
| Precancerous Conditions | 1 | 1996 | 189 | 0.010 |
Why?
| Ovarian Neoplasms | 1 | 1993 | 675 | 0.000 |
Why?
|
|
Talamonti's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|